SA
AMED

Shilanski & Associates’s Amedisys AMED Stock Holding History

Shilanski & Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,864
Closed -$1.29M – 113
2021
Q1 		$1.29M Sell
4,864
-177
-4% -$49.9K 0.69% 48
2020
Q4 		$1.48M Buy
5,041
+46
+0.9% +$11.8K 0.9% 39
2020
Q3 		$1.18M Buy
4,995
+28
+0.6% +$6.37K 0.8% 38
2020
Q2 		$986K Buy
4,967
+99
+2% +$18.5K 0.72% 44
2020
Q1 		$893K Buy
4,868
+54
+1% +$9.61K 0.9% 33
2019
Q4 		$804K Buy
+4,814
New +$716K 0.62% 49

Other funds holding AMED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Shilanski & Associates's AMED Position: Q2 2021 in Review

Shilanski & Associates sold out of Amedisys (AMED) in Q2 2021, closing a stake of 4,864 shares — an estimated $1.29M sold.

Shilanski & Associates first reported a position in AMED in Q4 2019 and held it in 6 quarters. The position peaked at $1.48M in Q4 2020. 376 funds tracked by Wall St. Rank hold AMED as of Q2 2021.

  • Shilanski & Associates reported no remaining Amedisys position as of Q2 2021 after selling out during the quarter.
  • Shilanski & Associates sold 4,864 Amedisys shares in Q2 2021, an estimated $1.29M.
  • Shilanski & Associates first reported a position in Amedisys in Q4 2019 and held it in 6 quarters.
  • Shilanski & Associates's Amedisys position peaked at $1.48M in Q4 2020.
  • 376 funds tracked by Wall St. Rank held Amedisys as of Q2 2021.

Based on Shilanski & Associates's 13F filing for Q2 2021, filed 13 Aug 2021.